Literature DB >> 15008800

Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis.

T J Huber1, M Borsutzky, U Schneider, H M Emrich.   

Abstract

OBJECTIVE: The aim of this study was to further evaluate the oestrogen hypothesis of schizophrenia, which postulates low oestradiol levels to be a risk factor for these disorders. A possible influence of neuroleptic-induced hyperprolactinaemia was to be addressed.
METHOD: Sex hormones were measured and cycle phase assessed in 50 acutely psychotic women on admission and for four consecutive weeks as well as in three control groups.
RESULTS: Psychotic women were more likely to be admitted during a low oestrogen phase of their cycle and exhibited markedly reduced oestradiol levels, compared with 23 healthy controls, as well as 50 women suffering from other psychiatric disorders. Oestradiol variability was reduced over the menstrual cycle in women suffering from psychotic disorders.
CONCLUSION: These results support the oestrogen hypothesis. Hyperprolactinaemia due to neuroleptic treatment does not appear to account for the findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15008800     DOI: 10.1046/j.1600-0447.2003.00251.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  27 in total

1.  Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-07-07       Impact factor: 7.853

Review 2.  Epigenetics, oestradiol and hippocampal memory consolidation.

Authors:  K M Frick
Journal:  J Neuroendocrinol       Date:  2013-11       Impact factor: 3.627

Review 3.  Building a better hormone therapy? How understanding the rapid effects of sex steroid hormones could lead to new therapeutics for age-related memory decline.

Authors:  Karyn M Frick
Journal:  Behav Neurosci       Date:  2012-02       Impact factor: 1.912

4.  Successful use of adjuvant phytoestrogens in schizoaffective disorder: a case report.

Authors:  Balaji Bharadwaj; Rashmi Arasappa; Ganesan Venkatasubramanian; Bangalore N Gangadhar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

5.  Exposure to traffic pollutants and effects on 17-beta-estradiol (E2) in female workers.

Authors:  Gianfranco Tomei; Manuela Ciarrocca; Bruna Rita Fortunato; Assunta Capozzella; Maria Valeria Rosati; Daniela Cerratti; Enrico Tomao; Vincenza Anzelmo; Carlo Monti; Francesco Tomei
Journal:  Int Arch Occup Environ Health       Date:  2006-05-06       Impact factor: 3.015

6.  Menstrual Cycle in Schizophrenic Patients: Review with a Case.

Authors:  İpek Sönmez; Ferdi Köşger
Journal:  Noro Psikiyatr Ars       Date:  2015-12-01       Impact factor: 1.339

Review 7.  Olanzapine versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Lorna Duggan; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

8.  Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-03-17       Impact factor: 7.853

9.  Expression of the hippocampal NMDA receptor GluN1 subunit and its splicing isoforms in schizophrenia: postmortem study.

Authors:  Monika Vrajová; Frantisek Stastný; Jirí Horácek; Jan Lochman; Omar Serý; Sona Peková; Jan Klaschka; Cyril Höschl
Journal:  Neurochem Res       Date:  2010-03-05       Impact factor: 3.996

Review 10.  Quetiapine versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Franziska Schmid; Heike Hunger; Sandra Schwarz; Manit Srisurapanont; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.